Skip to main content
Clinical Trials/CTRI/2023/03/050635
CTRI/2023/03/050635
Not yet recruiting
Phase 3

Evaluation of visual, refractive outcome and changes in the ocular parameters after Eyecryl phakic IOL implementation in patients with moderate to high myopia and astigmatism: A prospective comparative study with EVO/EVO+ Visian implantable lenses

Prof MVanathi0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: H521- Myopia
Sponsor
Prof MVanathi
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Prof MVanathi

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with myopic astigmatism within a spherical equivalent (SE) range of \-3\.00 to \-20\.00 D and a minimum astigmatism of \-1\.00 D, stable refraction (0\.50 D or less change in the past 12 months),
  • 2\.Minimum anterior chamber depth (ACD) from corneal endothelium of 2\.8 mm,
  • 3\.Endothelial cell count of 2,500 cells/mm2
  • 4\.Absence of corneal ectatic diseases, corneal scars,
  • 5\.Absence of retinal pathologies
  • 6\.Patients willing to give written informed consent and attend all follow\-up appointments

Exclusion Criteria

  • 1\.Subject with previous intraocular or corneal surgery
  • 2\.Subject with ocular condition like any cataract of any grade, glaucoma, severe dry eye, herpetic keratitis, uveitis
  • 3\.Subject with systemic conditions like diabetes, collagen vascular diseases, immunosuppression
  • 4\.Subject who is Pregnant or planning to start family, or lactating during the course of the evaluation
  • 5\.Other condition associated with fluctuation of hormones
  • 6\.Monocular subject
  • 7\.Patient not willing to give written informed consent and attend all follow\-up appointments

Outcomes

Primary Outcomes

Not specified

Similar Trials